Clinical trial · Observational
PET Tracer Based FDG Signal for Predicting Prognosis in Acute Myeloid Leukemia
The Efficiency of 18F-FDG PET Probe Signal in Bone Marrow for Predicting Acute Myeloid Leukemia Patients' Response to Induction Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the predictive value of 18F-FDG PET probe signal in de novo diagnosed or refractory/relapsed patients with acute myeloid leukemia. It is hypothesized that the intensity of 18F-FDG signal, an indicator of glucose uptake capacity, in various cell subsets of bone marrow will improve the predictive effect of clinical standard prognostic work-up.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- AML patients, de novo or refractory/relapsed
- description
- The investigators will collect bone marrow cells under standard clinical work-up after 18F-FDG PET/CT scan and correlate the FDG signal with extramedullary infiltration, histopathological, genomics features of the patients to explore the prognostic value of FDG signal in AML.
- interventionNames
- Other: No intervention
Primary outcomes (1)
- measure
- Composite complete remission rate (CRc)
- timeFrame
- At the end of Cycle 2 (each cycle is about 28 days)
- description
- Partial response (PR) + complete response (CR) rate
Secondary outcomes (1)
- measure
- Progress-free survival (PFS )
- timeFrame
- From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of Acute myeloid leukemia, non APL * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Patients voluntarily participated in this study and signed the informed consent Exclusion Criteria: * Pregnant * Uncontrolled systemic diseases (such as diabetes, non controlled heart failure, etc.)
References
Publications (0)
Data not yet available